The accumulating knowledge of human genomic variation is beingused for the development of personalized medicine, with theaims of decreasing the number of adverse drug reactions andincreasing the efficacy of drug treatment. Considerable pharmacogenomicresearch has focused on understanding the molecular mechanismsbehind adverse drug reactions and finding biomarkers that identifypeople at risk.
Serious adverse drug reactions have been shown to cause or contributeto 6 to 7% of all hospitalizations, a 2-day increase in theaverage length of hospitalization, and 100,000 deaths annuallyin the United States — and may, according to some estimates,cost about . . . [Full Text of this Article]
Source Information
From the Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm.
This article has been cited by other articles:
Harrill, A. H., Watkins, P. B., Su, S., Ross, P. K., Harbourt, D. E., Stylianou, I. M., Boorman, G. A., Russo, M. W., Sackler, R. S., Harris, S. C., Smith, P. C., Tennant, R., Bogue, M., Paigen, K., Harris, C., Contractor, T., Wiltshire, T., Rusyn, I., Threadgill, D. W.
(2009). Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res
19: 1507-1515
[Abstract][Full Text]
(2008). Pharmacogenetics Comes of Age!. Journal Watch Dermatology
2008: 2-2
[Full Text]
Previous
